Zoetis Inc (ZTS) Shares Sold by Tower Research Capital LLC TRC

Share on StockTwits

Tower Research Capital LLC TRC lessened its holdings in shares of Zoetis Inc (NYSE:ZTS) by 70.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,115 shares of the company’s stock after selling 17,001 shares during the period. Tower Research Capital LLC TRC’s holdings in Zoetis were worth $651,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ZTS. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Zoetis by 3,033.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after buying an additional 1,365 shares during the last quarter. Smith Asset Management Group LP grew its holdings in shares of Zoetis by 3.2% during the second quarter. Smith Asset Management Group LP now owns 117,240 shares of the company’s stock worth $9,988,000 after purchasing an additional 3,670 shares during the last quarter. Bbva Compass Bancshares Inc. grew its holdings in shares of Zoetis by 9.3% during the second quarter. Bbva Compass Bancshares Inc. now owns 9,223 shares of the company’s stock worth $786,000 after purchasing an additional 786 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Zoetis during the second quarter worth $4,315,000. Finally, Fiduciary Trust Co. grew its holdings in shares of Zoetis by 15.6% during the second quarter. Fiduciary Trust Co. now owns 16,546 shares of the company’s stock worth $1,410,000 after purchasing an additional 2,227 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.

Several equities analysts have weighed in on ZTS shares. JPMorgan Chase & Co. raised Zoetis from a “neutral” rating to an “overweight” rating and set a $100.00 target price on the stock in a research note on Monday, October 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $98.00 price objective on shares of Zoetis in a report on Monday, October 1st. Morgan Stanley set a $100.00 price objective on Zoetis and gave the stock a “hold” rating in a report on Friday, November 2nd. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective for the company. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a research note on Monday, September 10th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and an average target price of $94.00.

ZTS opened at $88.09 on Friday. Zoetis Inc has a 12-month low of $70.20 and a 12-month high of $96.57. The company has a market capitalization of $43.44 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 1.78 and a beta of 0.99. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The company had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period last year, the firm posted $0.65 earnings per share. The business’s revenue was up 9.9% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis Inc will post 3.11 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Tuesday, November 20th were issued a dividend of $0.126 per share. The ex-dividend date was Monday, November 19th. This represents a $0.50 annualized dividend and a yield of 0.57%. Zoetis’s payout ratio is currently 20.83%.

In related news, Director Willie M. Reed sold 3,205 shares of Zoetis stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $93.74, for a total transaction of $300,436.70. Following the completion of the sale, the director now directly owns 566 shares of the company’s stock, valued at approximately $53,056.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Juan Ramon Alaix sold 150,306 shares of Zoetis stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $94.96, for a total value of $14,273,057.76. Following the sale, the chief executive officer now directly owns 246,319 shares of the company’s stock, valued at $23,390,452.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 169,511 shares of company stock valued at $16,081,299. 0.35% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first posted by Equities Focus and is owned by of Equities Focus. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.equitiesfocus.com/2018/12/08/zoetis-inc-zts-shares-sold-by-tower-research-capital-llc-trc.html.

Zoetis Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Recommended Story: What are municipal bonds?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply